Pregnancy RSV vaccine slashes newborn hospital admissions by over 80%

A vaccine given during pregnancy is significantly cutting hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a reduction of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by boosting maternal immunity and transferring immunity through the placenta. A significant recent study analysing nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the period when infants are particularly susceptible to the virus. RSV affects roughly half of all newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.

How the immunisation protects at-risk babies

RSV, or respiratory syncytial virus, is a common respiratory infection that affects approximately half of all newborns during their first few months of life. The virus can vary from causing mild, cold-like symptoms to triggering severe chest infections that cause babies to struggle to breathe and feed. In the most serious cases, the lung inflammation becomes life-threatening, with small numbers of infants dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of severe RSV infections: “In babies with severe infections you can see their chest and lungs working hard, as they try to pull enough oxygen in. This is very, very frightening as a parent, frightening with good reason.”

The pregnancy vaccine works by activating the mother’s body’s defences to produce defence proteins, which are then transferred to the developing baby through the placenta. This mother-derived protection offers newborns with immediate protection from the point of delivery, exactly when they are highly susceptible to RSV. The latest research shows that protection reaches nearly 85 per cent when the vaccine is given at least four weeks before delivery. Even shorter intervals between vaccination and birth can still provide substantial defence, with evidence suggesting that a two-week gap is adequate to shield babies delivered prematurely. Dr Watson recommends pregnant women to receive the vaccine on schedule, whilst noting that protection can still occur even if administered later in the third trimester.

• Nearly 85 per cent protection when vaccinated 4 weeks before birth
• Maternal antibodies transferred through placenta safeguard newborns from day one
• Protection achievable with 2-week gap before early delivery
• Vaccination in the third trimester still offers significant infant protection

Persuasive evidence from current research

The efficacy of the pregnancy RSV vaccine has been confirmed through a thorough investigation conducted across England, examining data from nearly 300,000 babies born between September 2024 and March 2025. This represents approximately nine out of ten of all births during that six-month period, providing comprehensive and reliable evidence of the vaccine’s practical effectiveness. The study’s conclusions have been validated by the UK Health Security Agency as showing “excellent protection” for newborns during their most critical early weeks. The breadth of this investigation gives healthcare professionals and prospective parents with confidence in the vaccine’s established performance across varied populations and settings.

The results paint a striking picture of the vaccine’s protective effectiveness. More than 4,500 babies were admitted to hospital with RSV throughout the study period, with the vast majority being infants whose mothers had not been given the vaccination. This marked difference emphasises the vaccine’s essential role in protecting against serious illness in newborns. The reduction in hospital admissions exceeding 80 per cent represents a substantial public health milestone, helping to prevent thousands of infants from experiencing the frightening and potentially life-threatening symptoms linked to severe RSV infection. These findings strengthen the importance of the vaccination programme launched in the UK in 2024.

Research approach and coverage

The research reviewed birth and hospitalisation records from England over a six-month timeframe, capturing data on approximately 90 per cent of all births during this timeframe. By examining nearly 300,000 babies born to vaccinated and unvaccinated mothers, researchers were able to establish direct comparisons of RSV infection levels and hospital admissions. The large sample size and thorough nature of the data collection ensured that findings were statistically robust and reflective of the wider population, rather than isolated cases or limited subgroups.

The study specifically tracked hospital admissions for RSV among infants born to mothers who had received the vaccine at differing periods before delivery. This allowed researchers to determine the least amount of time between vaccination and birth for maximum protection, as well as to determine whether protection stayed significant with shorter intervals. The methodology assessed practical outcomes rather than controlled laboratory conditions, providing tangible evidence of how the vaccine performs when administered across varied healthcare environments and patient circumstances throughout pregnancy’s final trimester.

Learning about RSV and its threats

Respiratory syncytial virus, commonly referred to as RSV, is among the primary causes of hospitalisation in infants aged under twelve months across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their first few months of life, with severity changing substantially from minor cold-type symptoms to serious, potentially fatal chest infections. Over 20,000 infants require serious hospital treatment for RSV annually in the UK alone, placing enormous strain on children’s wards and newborn care units during peak seasons.

The infection produces deep inflammation in the lungs and airways, making it extremely challenging for infected babies to breathe and feed adequately. Parents often witness their babies fighting for breath, their chests rising whilst they try to pull adequate oxygen into their weakened respiratory system. Whilst most infants get better with clinical support, a modest yet notable number die from respiratory syncytial virus complications yearly, making vaccination as prevention a essential public health imperative for defending the youngest and most at-risk individuals in the population.

• RSV produces inflammation in lungs, resulting in serious respiratory problems in babies
• Half of all newborns catch the infection during their first few months alive
• Symptoms span from minor cold-like symptoms to serious chest infections that threaten life requiring hospitalisation
• More than 20,000 UK infants need serious hospital treatment for RSV each year
• Small numbers of infants die from RSV related complications annually in the UK

Uptake rates and specialist advice

Since the RSV vaccine programme launched in 2024, health officials have stressed the importance of pregnant women getting their jab at the best time for greatest protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has underscored that timing matters greatly for guaranteeing newborns benefit from the strongest possible immunity from birth. Whilst the research shows that vaccination at least four weeks before delivery provides approximately 85% protection, experts recommend women to receive their vaccine as early as possible from 28 weeks of pregnancy onwards to increase the antibodies passed to their babies via the placenta.

The guidance from public health bodies stays clear: pregnant women should prioritise vaccination during their final three months, even if circumstances mean they cannot get vaccinated at the ideal window. Dr Watson has reassured expectant mothers that protection remains still achievable with reduced timeframes between immunisation and delivery, including even a two-week gap for those giving birth ahead of schedule. This flexible approach recognises the realities of pregnancy and childbirth whilst maintaining strong protection for vulnerable newborns during their most critical early months when RSV represents the highest danger of serious illness.

Regional differences in vaccine uptake

Whilst the RSV vaccine programme has been rolled out across England, uptake rates and deployment schedules have varied across different regions and NHS trusts. Some areas have achieved greater immunisation rates among eligible pregnant women, whilst others remain focused to increase awareness and access to the jab. These regional differences reflect variations in medical facilities, communication strategies, and local engagement efforts, though the national data shows robust and reliable protection regardless of geographical location.

• NHS trusts rolling out multiple messaging strategies to engage with pregnant women
• Inconsistencies across regions in immunisation take-up throughout England necessitate strategic intervention
• Regional health providers adapting programmes to meet local requirements and situations

Real-world impact and parental perspectives

The vaccine’s impressive effectiveness translates into tangible benefits for families across the United Kingdom. With over 20,000 babies hospitalised annually due to RSV prior to the introduction of this safeguarding intervention, the 80% reduction in admissions means thousands of infants shielded from severe infection. Parents no more face the distressing scenario of seeing their babies gasping for air or labour to feed, symptoms that define serious RSV disease. The vaccine has fundamentally shifted the picture of neonatal respiratory health, providing expectant mothers a preventative option to shield their most vulnerable children during those vital initial period.

For families like that of Malachi, whose severe RSV infection led to profound brain damage, the vaccine’s availability carries significant emotional significance. His mother’s support of the jab emphasises the transformative consequences that preventable illness can have on young children and their families. Whilst Malachi’s experience predates the vaccine programme, his story strikes a chord with parents now offered protection. The knowledge that such significant complications—hospitalisation, oxygen dependency, neurological damage—are now largely preventable has given considerable reassurance to expectant mothers during their late pregnancy, changing what was once an predictable seasonal threat into a manageable health risk.